Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Primary effusion lymphoma (PEL) is a type of body cavity–based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden. Materials and Methods We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea. Results Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)–unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival. Conclusion PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.
Abstract
Purpose Primary effusion lymphoma (PEL) is a type of body cavity–based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden. Materials and Methods We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea. Results Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)–unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival. Conclusion PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.
참고문헌 (29)
- Chen YB, "Primary effusion lymphoma", Oncologist, 12, pp.569~576 (2007)
- Cesarman E, "Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas", N Engl J Med, 332, pp.1186~1191 (1995)
- Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
- Nador RG, "Primary effusion lymphoma : a distinct clinicopathologic entity associated with the Kaposi's sarcomaassociated herpes virus", Blood, 88, pp.645~656 (1996)
- Boulanger E, "A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients", Hematol J, 2, pp.172~179 (2001)
- Simonelli C, "Clinical features and outcome of primary effusion lymphoma in HIV-infected patients : a single-institution study", J Clin Oncol, 21, pp.3948~3954 (2003)
- Boulanger E, "Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS", J Clin Oncol, 23, pp.4372~4380 (2005)
- Guillet S, "Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution", Am J Hematol, 91, pp.233~237 (2016)
- Said JW, "Primary effusion lymphoma in women : report of two cases of Kaposi's sarcoma herpes virus-associated effusionbased lymphoma in human immunodeficiency virus-negative women", Blood, 88, pp.3124~3128 (1996)
- Jones D, "Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient", N Engl J Med, 339, pp.444~449 (1998)
- Boulanger E, "Human herpesvirus-8(HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin", Am J Transplant, 8, pp.707~710 (2008)
- Hermine O, "Body-cavitybased lymphoma in an HIV-seronegative patient without Kaposi's sarcoma-associated herpesvirus-like DNA sequences", N Engl J Med, 334, pp.272~273 (1996)
- Rodriguez J, "Primary effusion lymphoma in an HIV-negative patient with no serologic evidence of Kaposi's sarcoma virus", Leuk Lymphoma, 41, pp.185~189 (2001)
- Matsumoto Y, "Human herpesvirus 8-negative malignant effusion lymphoma : a distinct clinical entity and successful treatment with rituximab", Leuk Lymphoma, 46, pp.415~419 (2005)
- 신정훈, "Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone", Cancer Research and Treatment, 49(1), pp.274~278 (2017), 대한암학회
- Kobayashi Y, "Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8unrelated primary effusion lymphoma-like lymphoma on the basis of HIV : report of 2 cases and review of 212 cases in the literature", Acta Haematol, 117, pp.132~144 (2007)
- Alexanian S, "KSHV", HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states, 2013, pp.37, 241~249
- Wu W, "Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma : report of a rare case and review of 54 cases in the literature", Am J Clin Pathol, 140, pp.258~273 (2013)
- AIDS in the post-HAART era: manifestations, treatment, and epidemiology, "HIV", pp.2011, Hall JC
- Cheson BD, "Revised response criteria for malignant lymphoma", J Clin Oncol, 25, pp.579~586 (2007)
- Choe KW, "Epidemiology of HIV", AIDS : current status, trend and prospect, 2007, pp.50, 296~302
- Oksenhendler E, "Complete remission of a primary effusion lymphoma with antiretroviral therapy", Am J Hematol, 57, pp.266~ (1998)
- Hocqueloux L, "Longterm remission of an AIDS-related primary effusion lymphoma with antiviral therapy", AIDS, 15, pp.280~282 (2001)
- Carbone A, "Proliferation in HHV-8-positive primary effusion lymphomas is associated with expression of HHV-8cyclin but independent of p27(kip1)", Am J Pathol, 156, pp.1209~1215 (2000)
- Pro B, "Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma", Blood, 130, pp.2709~2717 (2017)
- Younes A, "Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma", J Clin Oncol, 30, pp.2183~2189 (2012)
- Connors JM, "Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma", N Engl J Med, 378, pp.331~344 (2018)
- Jacobsen ED, "Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed", refractory DLBCL with variable CD30 expression, 2015, pp.125, 1394~1402
- Bhatt S, "CD30 targeting with brentuximab vedotin : a novel therapeutic approach to primary effusion lymphoma", Blood, 122, pp.1233~1242 (2013)